13F Holdings
中文EN

NKTR NEKTAR THERAPEUTICS

Pharmaceutical Preparations · Nasdaq · SEC CIK 906709 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-16.6%
TTM net income YoY-46.8%
TTM EPS YoY18.0%
Revenue 3-yr CAGR-16.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-319.8%
Net margin-339.7%
FCF margin-493.4%
EBITDA margin-318.5%

Returns

ROE-37.9%
ROA-26.5%
ROIC (approx.)-30.7%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets18.1%
Debt / equity0.00x
Current ratio9.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.45x
Accruals ratio11.9%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$55.23M$98.43M$90.12M$92.06M$101.91M
Cost of revenue$0$30.69M$33.77M$21.64M$24.90M
Gross profit$55.23M$67.74M$56.35M$70.42M$77.01M
R&D expense$117.33M$120.91M$114.16M$218.32M$400.27M
SG&A expense$68.67M$76.75M$77.42M$92.33M$122.84M
Operating income-$140.10M-$105.20M-$263.68M-$376.17M-$446.10M
Interest expense———$0$0
Pretax income-$164.21M-$119.20M-$276.26M-$364.98M-$523.28M
Income tax-$138,000-$239,000-$200,000$3.21M$557,000
Net income-$164.08M-$118.96M-$276.06M-$368.20M-$523.84M
EBITDA-$139.08M-$100.81M-$256.68M-$363.97M-$433.10M
EPS (basic)-9.73-8.68-1.45-1.97-2.86
EPS (diluted)-9.73-8.68-1.45-1.97-2.86
Weighted avg. shares (diluted)16.87M13.71M190.00M187.14M183.30M
Balance sheet
Cash & equivalents$15.12M$44.25M$35.28M$88.23M$25.22M
Short-term investments$230.64M$210.97M$268.34M$416.75M$708.74M
Receivables—$0$1.21M$5.98M$22.49M
Inventory$0$0$16.10M$19.20M$15.80M
Current assets$266.27M$261.29M$330.70M$545.97M$795.58M
PP&E, net$2.06M$3.41M$18.86M$32.45M$60.51M
Goodwill——$0$76.50M$76.50M
Total assets$280.41M$303.85M$398.03M$710.60M$1.12B
Current liabilities$53.54M$61.40M$51.27M$68.20M$85.20M
Total liabilities$190.57M$243.11M$267.05M$343.96M$437.68M
Shareholders' equity$89.83M$60.74M$130.99M$366.64M$679.51M
Shares outstanding20.38M12.39M191.38M188.56M185.47M
Cash flow statement
Operating cash flow-$208.51M-$175.71M-$192.61M-$304.01M-$412.66M
Capital expenditure$171,000$1.47M$865,000$5.68M$14.99M
Free cash flow-$208.68M-$177.18M-$193.47M-$309.68M-$427.65M
Investing cash flow-$1.20M$142.57M$139.56M$365.83M$202.78M
Financing cash flow$180.57M$42.12M$30,000$1.51M$36.24M
Depreciation & amortization$1.03M$4.39M$7.00M$12.20M$13.00M
Stock-based compensation$12.65M$21.61M$33.39M$57.32M$94.67M
Share buybacks$0$3.00M$0——

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.